Monoclonal antibodies against large oval aggregates of Aβ1-42

Journal of Bioscience and Bioengineering

Volumn 115, Issue 2, 2013, Pages 216-220

  Shimizu, Takenori ^a   Yoshimune, Kazuaki ^a   Komoriya, Tomoe ^a   Akiyama, Takahiro ^b   Ye, Xujun ^c   Kohno, Hideki ^a  

^a NIHON UNIVERSITY   (Japan)

^b Immuno Probe Co Ltd   (Japan)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

A 1 42; Amorphous aggregates; Fibril form; Large oval aggregates; Monoclonal antibody

Indexed keywords

ALZHEIMER'S DISEASE; AMYLOID BETAS; CROSS-REACTIVITY; FIBRIL FORM; FIBRIL FORMATION; HIGH CONCENTRATION; HYBRIDOMA CELLS; M-FILTERS; SHEET STRUCTURE; SLOW ROTATION; TAPPING-MODE ATOMIC FORCE MICROSCOPY; THERAPEUTIC APPLICATION; THIOFLAVIN T;

CELL CULTURE; MONOCLONAL ANTIBODIES; SURFACE PLASMON RESONANCE;

AGGREGATES;

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; EPITOPE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MONOMER; THIOFLAVINE;

ALZHEIMER DISEASE; ANIMAL CELL; ANTIBODY SPECIFICITY; ARTICLE; ATOMIC FORCE MICROSCOPY; CELL LINE; CONCENTRATION (PARAMETERS); CROSS REACTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBER; FILTER; MOUSE; NONHUMAN; PROTEIN AGGREGATION; PROTEIN STRUCTURE; PURIFICATION; TEMPERATURE;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HUMANS; MICE; MICROSCOPY, ATOMIC FORCE; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, SECONDARY; THIAZOLES;

EID: 84871931208     PISSN: 13891723     EISSN: 13474421     Source Type: Journal    
DOI: 10.1016/j.jbiosc.2012.09.007     Document Type: Article

References (52)

1. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992, 256:184-185.
2. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
3. Kang J., Lemaire H.G., Unterbeck A., Salbaum J.M., Masters C.L., Grzeschik K.H., Multhaup G., Beyreuther K., Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987, 325:733-736.
4. Matsui T., Ingelsson M., Fukumoto H., Ramasamy K., Kowa H., Frosch M.P., Irizarry M.C., Hyman B.T. Expression of APP pathway mRNAs and proteins in Alzheimer's disease. Brain Res. 2007, 1161:116-123.
5. Jankowsky J.L., Fadale D.J., Anderson J., Xu G.M., Gonzales V., Jenkins N.A., Copeland N.G., Lee M.K., Younkin L.H., Wagner S.L., Younkin S.G., Borchelt D.R. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid protein in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 2004, 13:159-170.
6. Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B., Ross S., Amarante P., Loeloff R., other 14 authors Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999, 286:735-741.
7. Walter J., Fluhrer R., Hartung B., Willem M., Kaether C., Capell A., Lammich S., Multhaup G., Haass C. Phosphorylation regulates intracellular trafficking of beta-secretase. J. Biol. Chem. 2001, 276:14634-14641.
8. Esler W.P., Kimberly W.T., Ostaszewski B.L., Ye W., Diehl T.S., Selkoe D.J., Wolfe M.S. Activity-dependent isolation of the presenilin-gamma-secretase complex reveals nicastrin and a gamma substrate. Proc. Natl. Acad. Sci. USA 2002, 99:2720-2725.
9. Wolfe M.S., Kopan R. Intramembrane proteolysis: theme and variations. Science 2004, 305:1119-1123.
10. Sisodia S.S. Beta-amyloid precursor protein cleavage by a membrane-bond protease. Proc. Natl. Acad. Sci. USA 1992, 89:6075-6079.
11. Kimberly W.T., LaVoie M.J., Ostaszewski B.L., Ye W., Wolfe M.S., Selkoe D.J. Gamma-secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc. Natl. Acad. Sci. USA 2003, 100:6382-6387.
12. Suzuki N., Cheung T.T., Cai X.D., Odaka A., Otvos L., Eckman C., Golde T.E., Younkin S.G. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 1994, 264:1336-1340.
13. Bitan G., Tarus B., Vollers S.S., Lashuel H.A., Condron M.M., Straub J.E., Teplow D.B. A molecular switch in amyloid assembly: Met35 and amyloid beta-protein oligomerization. J. Am. Chem. Soc. 2003, 125:15359-15365.
14. Borchelt D.R., Thinakaran G., Eckman C.B., Lee M.K., Davenport F., Ratovitsky T., Prada C.M., Kim G., Seekins S., Yager D., other 10 authors Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta 1-42/1-40 ratio in vitro and in vivo. Neuron 1996, 17:1005-1013.
15. van Oijen M., Hofman A., Soares H.D., Koudstaal P.J., Breteler M.M.B. Plasma Aβ1-40 and Aβ1-42 and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 2006, 5:655-660.
16. Tjernberg L.O., Lilliehöök C., Callaway D.J., Näslund J., Hahne S., Thyberg J., Terenius L., Nordstedt C. Controlling amyloid beta-peptide fibril formation with protease-stable ligands. J. Biol. Chem. 1997, 272:12601-12605.
17. Youkin S.G. Evidence that A beta 42 is the real culprit in Alzheimer's disease. Ann. Neurol. 1995, 37:287-288.
18. Chafekar S.M., Malda H., Merkx M., Meijer E.W., Viertl D., Lashuel H.A., Baas F., Scheper W. Branched KLVFF tetramers strongly potentiate inhibition of beta-amyloid aggregation. Chembiochem 2007, 8:1857-1864.
19. Huong V.T., Shimanouchi T., Shimauchi N., Yagi H., Umakoshi H., Goto Y., Kuboi R. Catechol derivatives inhibit the fibril formation of amyloid-beta peptides. J. Biosci. Bioeng. 2010, 109:629-634.
20. LeVine H. Thioflavin T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 1993, 2:404-410.
21. Yoshiike Y., Chui D.H., Akagi T., Tanaka N., Takashima A. Specific compositions of amyloid-beta peptides as the determinant of toxic beta-aggregation. J. Biol. Chem. 2003, 278:23648-23655.
22. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell. Biol. 2007, 8:101-112.
23. Klein W.L., Stine W.B., Teplow D.B. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. Neurobiol. Aging 2004, 25:569-580.
24. Gong Y., Chang L., Viola K.L., Lacor P.N., Lambert M.P., Finch C.E., Krafft G.A., Klein W.L. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA 2003, 100:10417-10422.
25. Lambert M.P., Barlow A.K., Chromy B.A., Edwards C., Freed R., Liosatos M., Morgan T.E., Rozovsky I., Trommer B., Viola K.L., other 5 authors Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA 1998, 95:6448-6453.
26. Barghorn S., Nimmrich V., Striebinger A., Krantz C., Keller P., Janson B., Bahr M., Schmidt M., Bitner R.S., Harlan J., other 3 authors Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J. Neurochem. 2005, 95:834-847.
27. Lesné S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., Ashe K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
28. Chimon S., Shaibat M.A., Jones C.R., Calero D.C., Aizezi B., Ishii Y. Evidence of fibril-like β-sheet structures in a neurotoxic amyloid intermediate of Alzheimer's β-amyloid. Nat. Struct. Mol. Biol. 2007, 14:1157-1164.
29. Matsumura S., Shinoda K., Yamada M., Yokojima S., Inoue M., Ohnishi T., Shimada T., Kikuchi K., Masui D., Hashimoto S., other 14 authors Two distinct amyloid beta-protein (Abeta) assembly pathways leading to oligomers and fibrils identified by combined fluorescence correlation spectroscopy, morphology, and toxicity analyses. J. Biol. Chem. 2011, 286:11555-11562.
30. Deshpande A., Mina E., Glabe C., Busciglio J. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J. Neurosci. 2006, 26:6011-6018.
31. Hoshi M., Sato M., Matsumoto S., Noguchi A., Yasutake K., Yoshida N., Sato K. Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc. Natl. Acad. Sci. USA 2003, 100:6370-6375.
32. Vanderstichele H., Van Kerschaver E., Hesse C., Davidsson P., Buyse M.A., Andreasen N., Minthon L., Wallin A., Blennow K., Vanmechelen E. Standardization of measurement of beta-amyloid (1-42) in cerebrospinal fluid and plasma. Amyloid 2000, 7:245-258.
33. Horikoshi Y., Sakaguchi G., Becker A.G., Gray A.J., Duff K., Aisen P.S., Yamaguchi H., Maeda M., Kinoshita N., Matsuoka Y. Development of Abeta terminal end-specific antibodies and sensitive ELISA for Abeta variant. Biochem. Biophys. Res. Commun. 2004, 319:733-737.
34. Fukumoto H., Tennis M., Locascio J.J., Hyman B.T., Growdon J.H., Irizarry M.C. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch. Neurol. 2003, 60:958-964.
35. Dahlgren K.N., Manelli A.M., Stine W.B., Baker L.K., Krafft G.A., LaDu M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem. 2002, 277:32046-32053.
36. Tamagno E., Bardini P., Guglielmotto M., Danni O., Tabaton M. The various aggregation states of beta-amyloid 1-42 mediate different effects on oxidative stress, neurodegeneration, and BACE-1 expression. Free Radic. Biol. Med. 2006, 41:202-212.
37. Wu J.W., Breydo L., Isas J.M., Lee J., Kuznetsov Y.G., Langen R., Glabe C. Fibrillar oligomers nucleate the oligomerization of monomeric amyloid beta but do not seed fibril formation. J. Biol. Chem. 2009, 285:6071-6079.
38. Noguchi A., Matsumura S., Dezawa M., Tada M., Yanazawa M., Ito A., Akioka M., Kikuchi S., Sato M., Ideno S., other 11 authors Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from Alzheimer disease brains. J. Biol. Chem. 2009, 284:32895-32905.
39. Tjernberg L.O., Naslund J., Lindqvist F., Johansson J., Karlstrom A.R., Thyberg J., Terenius L., Nordstedt C. Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J. Biol. Chem. 1996, 271:8545-8548.
40. Khurana R., Coleman C., Ionescu-Zanetti C., Carter S.A., Krishna V., Grover R.K., Roy R., Singh S. Mechanism of thioflavin T binding to amyloid fibrils. J. Struct. Biol. 2005, 151:229-238.
41. Lyubchenko Y.L., Gall A.A., Shlyakhtenko L.S., Harrington R.E., Jacobs B.L., Oden P.I., Lindsay S.M. Atomic force microscopy imaging of double stranded DNA and RNA. J. Biomol. Struct. Dyn. 1992, 10:589-606.
42. Yamaguchi K., Takahashi S., Kawai T., Naiki H., Goto Y. Seeding-dependent propagation and maturation of amyloid fibril conformation. J. Mol. Biol. 2005, 352:952-960.
43. Koh C.J., Lee M. Structural analysis of amyloid aggregates by multifunctional fluorescence nanoscopy. Curr. Appl. Phys. 2006, 6S1:e257-e260.
44. Vincent V.A., DeVoss J.J., Ryan H.S., Murphy G.M. Analysis of neuronal gene expression with laser capture microdissection. J. Neurosci. Res. 2002, 69:578-586.
45. Lin S., Wang Y.M., Huang L.S., Lin C.W., Hsu S.M., Lee C.K. Dynamic response of glucagon/anti-glucagon pairs to pulling velocity and pH studied by atomic force microscopy. Biosens. Bioelectron. 2007, 22:1013-1019.
46. Köhler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497.
47. Jerne N.K., Nordin A.A. Plaque formation in agar by single antibody-producing cells. Science 1963, 140:405.
48. Cotton R.G.H., Secher D.S., Milstein C. Somatic mutation and the origin of antibody diversity. Clonal variability of the immunoglobulin produced by MOPC 21 cells in culture. Eur. J. Immunol. 1973, 3:135-140.
49. Komoriya T., Kikuchi M., Terashima Y., Okamoto M., Ogawa M., Moriyama M., Kohno H. Development of a highly sensitive latex reagent directed against C-reactive protein (CRP) using epitope analysis with monoclonal antibodies. Biosci. Biotechnol. Biochem. 2010, 74:292-297.
50. Wei C.W., Peng Y., Zhang L., Huang Q., Cheng M., Liu Y.N., Li J. Synthesis and evaluation of ferrocenoyl pentapeptide (Fc-KLVFF) as an inhibitor of Alzheimer's Aβ1-42 fibril formation in vitro. Bioorg. Med. Chem. Lett. 2011, 21:5818-5821.
51. Murakami K., Horikoshi-Sakuraba Y., Murata N., Noda Y., Masuda Y., Kinoshita N., Hatsuta H., Murayama S., Shirasawa T., Shimizu T., Irie K. Monoclonal antibody against the turn of the 42-residue amyloid β-protein at positions 22 and 23. ACS Chem. Neurosci. 2010, 1:747-756.
52. Armstrong R.A., Cairns N.J. Size frequency distribution of the beta-amyloid (abeta) deposits in dementia with Lewy bodies with associated Alzheimer's disease pathology. Neurol. Sci. 2009, 30:471-477.